A total of 709 unlicensed and off-label medicines were prescribed for 338 patients discharged from a paediatric hospital between 1 November 2003 and 31 January 2004. Thirty three per cent of patients had difficulty obtaining these medications in primary care which caused treatment disruption. The main problems were: (1) community pharmacies being unable to supply; and (2) GPs’ refusal to prescribe.
- general practitioners
Statistics from Altmetric.com
In the UK, a Marketing Authorisation (MA) granted by the Medicines and Healthcare products Regulatory Agency (MHRA) provides assurance that the medication has been evaluated for its safety, quality, and efficacy. However, due to various financial, ethical, and technical reasons, many medications have not been tested in children,1 and hence are not licensed to be used in children. The use of a medication outside the characteristics stated by the MA is given the term “off-label”, whereas “unlicensed medicines” are medicines without MAs. It is known that paediatric patients seen by a specialist paediatric hospital often experience difficulties in obtaining unlicensed and off-label medications after discharge. However, no previous study has been conducted to investigate this issue.
This study aimed to identify the availability of unlicensed and off-label medications for paediatric patients and their carers in primary care, after discharge from a specialist hospital, Great Ormond Street Hospital (GOSH) for Children, London.
The discharge prescription forms of patients leaving GOSH, London between 1 November 2003 and 31 January 2004 were reviewed by VY to extract information on: the patient’s date of birth, full name, hospital identification number, telephone number, medications, date of dispensing, and the date of discharge. The British National Formulary (BNF)2 and Summaries of Product Characteristics3 were used to classify medicines as off-label or unlicensed. Following this, structured telephone interviews were conducted with the families by NB to investigate the availability of unlicensed and off-label medication in primary care after discharge. A second interview was conducted with some GPs by VY to establish whether there was a specific reason why they did not prescribe for a child. Telephone interviews with carers and GPs were conducted between February and July 2004.
The study was approved by the Audit Department of GOSH in order to improve the pharmaceutical care of the patients. As a result ethical committee approval was not required.
During the study period, 1894 patients were discharged with 5976 prescription items. Twelve per cent (709/5976) of the medications prescribed were either unlicensed or off-label and were given to 338 of the paediatric patients. Fifty nine patients were excluded at this stage (2 with overseas addresses and 57 who did not have a telephone number).
A total of 279 patients with UK addresses and contact telephone numbers were categorised into four main divisions of age:4
Neonates (less than 1 month); 5 patients
Infants and toddlers (1–23 months); 121 patients
Children (2–11 years); 107 patients
Adolescents (12–18 years); 46 patients.
After the first telephone interviews, it was established that 40 carers did not provide the correct contact number, 11 patients were from overseas, 7 were deceased, and 5 were inpatients. Nine carers could not understand or speak the English language and had difficulty in answering the questions. Consequently 63 patients were excluded from the interview.
Seventy two of 216 carers (33%) reported problems in obtaining medications after being discharged. The results of the telephone interview are summarised in table 1.
Twenty six carers reported that their GPs had refused to prescribe the appropriate medication(s); in total 15 GPs participated in the second interview. One GP was on holiday and another carer did not provide the correct contact number for the GP. The remaining patients were prescribed readily available medication at the time of the study, hence there would not have been any problem obtaining these medications in general practice. Therefore the team decided to exclude these GPs from the study. Table 2 shows the medications that the GPs refused to prescribe to the 15 paediatric patients and the reasons for their refusal to prescribe.
At present, we are not aware of any published study that has investigated the availability of unlicensed and off-label medication to paediatric patients in UK primary care. This is probably the first study to investigate this systematically. This audit established that one third of the paediatric patients leaving GOSH face some difficulties in obtaining unlicensed and off-label medications in primary care. Unfortunately, some patients experienced disruption in their treatment; this could be life threatening. For example, one patient was prescribed tacrolimus for prevention of graft rejection following a heart transplant. Failure to obtain this medication could result in organ rejection; therefore it is vital that treatment is not disrupted.
It is understandable that pharmacies do not want to keep stocks of such medications, particularly “specials” products which usually have a very short expiry date. However, it is surprising to find that a number of pharmacies were unable to obtain these medications due to various reasons, such as being unable to locate the appropriate manufacturers, or manufacturers unable to produce the appropriate formulations. Many unlicensed medicines are extemporaneous products or “specials” products and many of them have to be prepared by specials manufacturers. Sometimes it is necessary to import foreign medicines. The lack of awareness of the availability and the sources of unlicensed medications among community pharmacists is due to the restrictions imposed by the Medicines Act. This prohibits companies promoting unlicensed or off-label use of medicines; consequently, community pharmacists are sometimes unable to locate the manufacturers. Although a new EU “Better Medicines for Children” regulation will give manufacturers the incentive to develop more paediatric medicines for in-patent drugs,5 it is unlikely to have any significant effects on the off-patent drugs. Therefore, the availability problems are unlikely to be resolved in the foreseeable future. Further studies in community pharmacies should be conducted to identify ways to improve the supply; however, it is important to involve the MHRA in any future studies.
General practice problems
The reasons for refusal stem mainly from the fact that GPs feel they do not have the relevant experience or expertise to prescribe to paediatric patients, particularly some with complicated cases. These are important and valid reasons for refusal to prescribe. In order to resolve the above problems, it is essential that the GP has access to sound information on any medication that he or she is to prescribe or administer, including the availability of the medications themselves. Making the BNF for Children available to all GPs is an important step towards tackling the problems in prescribing for children.
Other GPs have claimed that the medications some paediatric patients have been prescribed are too expensive to issue in primary care. Some GPs have also refused to prescribe because they do not have access to the correct equipment to monitor the pharmacokinetics. The above problems could be resolved by improving communication and shared treatment protocols.
Limitations of the study
GOSH is known to deal with complex cases and frequently treats children with serious and rare conditions. Therefore the results may not be common to other non-paediatric hospitals. However, other specialist paediatric hospitals in the UK are likely to encounter similar problems.
Children discharged from a specialist paediatric hospital frequently encounter problems in obtaining their unlicensed and off-label medicines in primary care. The results are likely to be applicable to other specialist paediatric hospitals. It is important to identify ways to improve the availability of these medications in primary care.
The authors wish to thank the participating families and GPs who took part in this study. Professor Wong’s post is funded by a UK Department of Health Public Health Career Scientist Award.
Published Online First 22 May 2006
Competing interests: none declared
Funding: The School of Pharmacy, University of London
Present address of V W Yeung: Medicines Healthcare products Regulatory Agency (MHRA), London, UK. The views expressed in this article do not represent the views of the MHRA.
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.